Tracking Japan's development assistance for health, 2012-2016.
Development assistance for health
Health policy
Japan
Journal
Globalization and health
ISSN: 1744-8603
Titre abrégé: Global Health
Pays: England
ID NLM: 101245734
Informations de publication
Date de publication:
15 04 2020
15 04 2020
Historique:
received:
12
09
2019
accepted:
13
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan's DAH from 2012 to 2016 and clarified its flows, including source, aid type, channel, target region, and target health focus area. Data on Japan Tracker, the first data platform of Japan's DAH, were used. The DAH definition was based on the Organisation for Economic Co-operation and Development's (OECD) sector classification. Regarding core funding to non-health-specific multilateral agencies, we estimated DAH and its flows based on the OECD methodology for calculating imputed multilateral official development assistance (ODA). Japan's DAH was estimated at 1472.94 (2012), 823.15 (2013), 832.06 (2014), 701.98 (2015), and 894.57 million USD (2016) in constant prices of 2016. Multilateral agencies received the largest DAH share of 44.96-57.01% in these periods, followed by bilateral grants (34.59-53.08%) and bilateral loans (1.96-15.04%). Ministry of Foreign Affairs (MOFA) was the largest contributors to the DAH (76.26-82.68%), followed by Ministry of Finance (MOF) (10.86-16.25%). Japan's DAH was most heavily distributed in the African region with 41.64-53.48% share. The channel through which the most DAH went was Global Fund to Fight AIDS, Tuberculosis, and Malaria (20.04-34.89%). Between 2012 and 2016, approximately 70% was allocated to primary health care and the rest to health system strengthening. With many major high-level health related meetings ahead, coming years will play a powerful opportunity to reevaluate DAH and shape the future of DAH for Japan. We hope that the results of this study will enhance the social debate for and contribute to the implementation of Japan's DAH with a more efficient and effective strategy.
Sections du résumé
BACKGROUND
Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan's DAH from 2012 to 2016 and clarified its flows, including source, aid type, channel, target region, and target health focus area.
METHODS
Data on Japan Tracker, the first data platform of Japan's DAH, were used. The DAH definition was based on the Organisation for Economic Co-operation and Development's (OECD) sector classification. Regarding core funding to non-health-specific multilateral agencies, we estimated DAH and its flows based on the OECD methodology for calculating imputed multilateral official development assistance (ODA).
RESULTS
Japan's DAH was estimated at 1472.94 (2012), 823.15 (2013), 832.06 (2014), 701.98 (2015), and 894.57 million USD (2016) in constant prices of 2016. Multilateral agencies received the largest DAH share of 44.96-57.01% in these periods, followed by bilateral grants (34.59-53.08%) and bilateral loans (1.96-15.04%). Ministry of Foreign Affairs (MOFA) was the largest contributors to the DAH (76.26-82.68%), followed by Ministry of Finance (MOF) (10.86-16.25%). Japan's DAH was most heavily distributed in the African region with 41.64-53.48% share. The channel through which the most DAH went was Global Fund to Fight AIDS, Tuberculosis, and Malaria (20.04-34.89%). Between 2012 and 2016, approximately 70% was allocated to primary health care and the rest to health system strengthening.
CONCLUSIONS
With many major high-level health related meetings ahead, coming years will play a powerful opportunity to reevaluate DAH and shape the future of DAH for Japan. We hope that the results of this study will enhance the social debate for and contribute to the implementation of Japan's DAH with a more efficient and effective strategy.
Identifiants
pubmed: 32293475
doi: 10.1186/s12992-020-00559-2
pii: 10.1186/s12992-020-00559-2
pmc: PMC7161223
doi:
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Commentaires et corrections
Type : ErratumIn
Références
Epidemiol Infect. 2008 Jul;136(7):980-7
pubmed: 17767793
Lancet. 2019 Jul 13;394(10193):173-183
pubmed: 31257126
Lancet. 2013 Sep 14;382(9896):915-6
pubmed: 24034284
Health Syst Reform. 2015 Jan 2;1(1):72-88
pubmed: 31519086
Front Physiol. 2012 Jun 19;3:198
pubmed: 22723781
Lancet. 2015 May 9;385(9980):1884-901
pubmed: 25987157
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Global Health. 2008 Mar 25;4:6
pubmed: 18364048
Health Econ. 2014 Feb;23(2):129-40
pubmed: 24327240
Health Policy Plan. 2017 May 1;32(4):493-503
pubmed: 28025320
Lancet. 2015 Dec 12;386(10011):2367-9
pubmed: 26700515
Lancet. 2018 May 5;391(10132):1783-1798
pubmed: 29678341
Lancet. 2018 Nov 10;392(10159):2091-2138
pubmed: 30496107
Med Confl Surviv. 2006 Jul-Sep;22(3):192-8
pubmed: 16961120
Glob Health Action. 2013 Mar 01;6:1-11
pubmed: 23458089
Lancet. 2019 Jun 1;393(10187):2233-2260
pubmed: 31030984
Lancet. 2016 May 21;387(10033):2155-2162
pubmed: 27301827
J Glob Health. 2018 Dec;8(2):020309
pubmed: 30410735
Lancet. 2010 Apr 17;375(9723):1375-87
pubmed: 20381856
Lancet. 2012 Jan 7;379(9810):9-10
pubmed: 21885097
Global Health. 2010 Aug 22;6:14
pubmed: 20727211
Lancet. 2018 Oct 6;392(10154):1217-1234
pubmed: 30266414
Lancet. 2015 Dec 12;386(10011):2436-41
pubmed: 26178405
Lancet. 2006 Sep 23;368(9541):1077-87
pubmed: 16997662
Bull World Health Organ. 2010 Dec 1;88(12):943-8
pubmed: 21124720
Health Policy Plan. 2007 Nov;22(6):353-62
pubmed: 17644556
Lancet. 2009 Jun 20;373(9681):2137-69
pubmed: 19541040